Elutia agrees to sell SimpliDerm business to Cellution Biologics for up to $11 million
ELUT•Focus shifts to NXT-41x
The divestiture shifts Elutia’s focus to NXT-41x, targeting a 2027 commercial launch in U.S. plastic and reconstructive surgery.
Elutia to sell SimpliDerm business
Elutia signed a definitive deal to sell its SimpliDerm human acellular dermal matrix business to Cellution Biologics for up to $11 million.
Terms include $8 million cash at closing, with up to $3 million tied to technology transfer and commercial milestones over 18 months.
Closing is expected in the second half of 2026, subject to customary conditions.
Related News
First Carolina Financial Services Chief Rev. & Strategy Officer Douglas Andrew Mathieson files initial beneficial ownership statement
FCBM•
JFB Construction amends Xtend merger deal, extends closing deadline to Oct. 31, 2026
JFB•
